Literature DB >> 21395654

Relative bioavailability of terbutaline to the lung following inhalation, using urinary excretion.

Mohamed E Abdelrahim1, Khaled H Assi, Henry Chrystyn.   

Abstract

AIMS: The aim of the study was to determine the relative lung and systemic bioavailability of terbutaline.
METHODS: On separate days healthy volunteers received 500 µg terbutaline study doses either inhaled from a metered dose inhaler or swallowed as a solution with and without oral charcoal. Urine samples were provided at timed intervals post dosing.
RESULTS: Mean (SD) urinary terbutaline 0.5 h post inhalation, in 12 volunteers, with (IC) and without (I) oral charcoal and oral (O) dosing was 7.4 (2.2), 6.5 (2.1) and 0.2 (0.2) µg. I and IC were similar and both significantly greater than O (P<0.001). Urinary 24 h terbutaline post I was similar to IC + O. The method was linear and reproducible, similar to that of the urinary salbutamol method.
CONCLUSIONS: The urinary salbutamol pharmacokinetic method post inhalation applies to terbutaline. Terbutaline study doses can replace routine salbutamol during these studies when patients are studied.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21395654      PMCID: PMC3080650          DOI: 10.1111/j.1365-2125.2010.03873.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  European Respiratory Society Guidelines on the use of nebulizers.

Authors:  J Boe; J H Dennis; B R O'Driscoll; T T Bauer; M Carone; B Dautzenberg; P Diot; K Heslop; L Lannefors
Journal:  Eur Respir J       Date:  2001-07       Impact factor: 16.671

2.  Dose-response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation.

Authors:  H S Tomlinson; S A Corlett; H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

3.  Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization.

Authors:  V L Silkstone; S A Corlett; H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

4.  Determination of the relative bioavailability of salbutamol to the lung following inhalation.

Authors:  M Hindle; H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

5.  New HPLC assay for urinary salbutamol concentrations in samples collected post-inhalation.

Authors:  S H R A Mazhar; H Chrystyn
Journal:  J Pharm Biomed Anal       Date:  2009-04-11       Impact factor: 3.935

6.  Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices.

Authors:  M Hindle; H Chrystyn
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

7.  A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline.

Authors:  L Borgström; M Nilsson
Journal:  Pharm Res       Date:  1990-10       Impact factor: 4.200

  7 in total
  2 in total

1.  Urinary pharmacokinetic methodology to determine the relative lung bioavailability of inhaled beclometasone dipropionate.

Authors:  Amira S A Said; Lindsay P Harding; Henry Chrystyn
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

2.  Effect of age of COVID-19 inpatient on the severity of the disease: A meta-analysis.

Authors:  Shaoqing Chai; Yan Li; Xuemei Li; Jie Tan; Mohamed E A Abdelrahim; Xiaoxiao Xu
Journal:  Int J Clin Pract       Date:  2021-08-01       Impact factor: 3.149

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.